A multicentre retrospective study published in Frontiers has compiled preliminary data on thalidomide used as a rescue protocol for dogs with multiple myeloma, putting a long-established human drug on the radar of veterinary oncologists who treat relapsed plasma-cell disease.

The study aggregates medical records from multiple veterinary centres, pooling cases of canine multiple myeloma in which thalidomide entered the treatment plan after standard therapy stopped controlling disease. The authors classify their findings as preliminary, a label that flags both the early stage of the evidence and the structural limits of retrospective data.

What the paper positions thalidomide to do

The full text identifies thalidomide as a rescue protocol rather than a first-line treatment. In canine multiple myeloma, first-line chemotherapy typically induces remission in a majority of dogs, but relapse is common. A "rescue" or "salvage" designation means thalidomide is positioned for the post-relapse setting, where it would compete with second-line chemotherapy options and palliative strategies.

Because the paper is retrospective, dogs in the dataset received varied doses and schedules across centres. The authors do not claim a standardised regimen, and the term "rescue protocol" reflects the clinical context of use rather than a fixed dosing blueprint.

Why thalidomide is being revisited in dogs

Thalidomide is an immunomodulatory drug first marketed in the late 1950s. It was withdrawn globally after the thalidomide embryopathy crisis of 1960-1962 and reintroduced in 1998, first for erythema nodosum leprosum and subsequently for multiple myeloma in human patients, where it now forms part of standard combination therapy.

The drug works through angiogenesis inhibition and cytokine modulation, mechanisms relevant to the bone-marrow microenvironment in which plasma cells proliferate. In human oncology, thalidomide and its analogues lenalidomide and pomalidomide have restructured treatment of both newly diagnosed and relapsed multiple myeloma. Veterinary medicine has not had a comparable agent with that mechanistic profile.

Regulatory status for veterinary use

In the United States, the FDA Center for Veterinary Medicine has not approved thalidomide for any canine indication. Veterinary use falls under the Animal Medicinal Drug Use Clarification Act (AMDUCA) extra-label framework, with the drug sourced from human pharmacies or compounders.

In the European Union, the European Medicines Agency has likewise not authorised thalidomide for veterinary use. Any practitioner prescribing it in dogs is working under cascade or extra-label provisions.

The teratogenicity signal that originally defined thalidomide's history remains the dominant safety consideration. Any veterinary use in a household with a pregnant owner or handler requires explicit counselling, and clinical staff should handle the drug as a hazardous agent.

What the multicentre retrospective design offers, and where it falls short

Multicentre retrospective case series allow aggregation of a rare-disease population no single hospital could assemble quickly. Canine multiple myeloma is uncommon, and the pooled approach gives the dataset a sample size that single-centre experience cannot match.

The trade-off is heterogeneity. Dosing schedules, concurrent medications, response criteria, and follow-up intervals vary by site, and a retrospective design cannot establish a dose-response curve. The authors' framing of the data as preliminary acknowledges these constraints and positions the work as a foundation for prospective evaluation.

What changes at the exam table

For practising veterinarians, the existence of a multicentre dataset on thalidomide in canine multiple myeloma lowers the evidentiary threshold for considering the drug as a rescue option when first-line therapy fails. It does not, on its own, define a dose, a schedule, or a response rate.

Owners considering thalidomide for a dog with relapsed multiple myeloma should receive explicit counselling on teratogenicity, on the off-label regulatory status, and on the preliminary nature of the available evidence. They should understand that the drug in this setting is a salvage candidate, not a standard of care.

Prospective trials, or accumulation of further retrospective cases with standardised reporting, will determine whether thalidomide moves from a rescue option to a defined component of canine myeloma protocols.